摘要
目的 :mdr 1基因是肿瘤多药耐药现象中的主要表型 ,探讨mdr 1基因原发耐药与继发耐药表达状况 ,预期指导临床个体化疗。方法 :应用RT PCR方法对 5 1例恶性肿瘤患者外周血淋巴细胞mdr 1基因进行定量体外诱导后检测其表达水平。结果 :5 1例外周血淋巴细胞中原发性阴性表达 34例占 6 6 % ,继发性阴性表达仅 5例占 9.8% ,外周血中的原发mdr 1阴性表达与继发性表达比较有显著性差异 (P <0 .0 1)。在低阳性组 ,原发性表达 11例占 2 1% ,继发性表达 31例占 6 0 .7% (P <0 .0 1)。高阳性组原发性表达 6例占 11.8% ,继发性表达 15例占 2 9% (P <0 .0 1)。继发性表达率明显高于原发性。 结论 :RT PCR检测人外周血淋巴细胞mdr 1基因表达取材方便 ,结果可靠 ,提示不同程度的mdr 1基因表达水平可以客观地反映不同个体的药物耐受情况 .
Purpose: To probe into the inherent and acquired expression of mdr 1 gene on drug resistance.Methods: Reverse transcription polymerase chain reaction ( RT PCR ) assay was used to detect the inherent and acquired expression of mdr 1 in the peripheral lymphocytes of 51 patients with malignant tumours. Results: There were 66 % (11/51) inherent and 9.8 % (5/51) acquired expression in negative groups, and 21% (11/51) inherent and 60.7 % (31/51) acquired in low positive groups, and 11.8 % (6/51) inherent and 29 % (15/51) acquired expression in high positive groups. Obvious differences were demonstrated among the three groups (P<0.01). Conclution: The results showed that the mdr 1 expression level can reflect the situation of drug resistance. The method using RT PCR assay to detect mdr 1 expression in the peripheral lymphocytes is convenient for selecting sensitive drugs.
出处
《癌变．畸变．突变》
CAS
CSCD
2002年第4期226-228,共3页
Carcinogenesis,Teratogenesis & Mutagenesis
基金
河南省科技攻关项目资助课题 (0 0 1170 2 0 5 )
